No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
HLS Therapeutics GAAP EPS of -$0.18, Revenue of $14.52M
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call
Shareholders in HLS Therapeutics (TSE:HLS) Are in the Red If They Invested Three Years Ago
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence With Clozapine Treatment
HLS Therapeutics Inc Price Target Cut to C$3.75/Share From C$4.15 by Stifel Nicolaus
HLS Therapeutics EPS of -$0.19 Beats by $0.04, Revenue of $12.5M Misses by $7.73M